Filter Search


Healthcare and Medical


Location Summary Deadline
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Bosutinib (l01ea04) Within The Framework Of A So-called Open House Model. 2026-08-31
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Edoxaban (b01af03) Within The Framework Of A So-called Open House Model. 2026-08-31
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Olanzapine (n05ah03), Without Solid Oral Dosage Forms Within The Framework Of A So-called O 2026-08-31
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Golimumab (l04ab06) Within The Framework Of A So-called Open House Model. 2026-08-31
Germany Medicines Containing The Active Ingredient Treprostinil (atc 2026-08-31
Germany Medicines Containing The Active Ingredient Erythropoietin (atc 2026-08-31
Germany Medicines Containing The Active Ingredient Erythropoietin (atc 2026-08-31
Germany Medicines Containing The Active Ingredient Lipegfilgrastim (atc 2026-08-31
Germany Open House Multipliers For Health Promotion In Schools 2026-08-31
Germany Open House Drug Rebate Agreements Naproxen, Atc M01ae02 2026-09-05
Whats app